Browse All

Current Filters

CLEAR FILTER x

TITLE

Outcomes of COVID-19 in Ofatumumab-treated Patients with RMS: Data from the ALITHIOS Open-label Extension Study

Author:Boer, Ibolya   Cree, Bruce   Wiendl, Heinz   Cross, Anne   Delgado, Sylvia   Habek, Mario   Khachanova, Natalia   Ward, Brian   Totolyan, Natalia   Mancione, Linda   Sullivan, Roseanne   Zielman, Ronald   Hu, Xixi   Das Gupta, Ayan   Montalban, Xavier   Winthrop, Kevin   

Session Name:P1: Multiple Sclerosis: Clinical Practice and Decision Making 1  

Topic:Multiple Sclerosis  

Program Number:P1.010  

Author Institution:Novartis Pharma AG, Basel, Switzerland  UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA  Department of Neurology with Institute of Translational Neurology, University of Münster, Muenster, Germany  Washington University School of Medicine, Saint Louis, MO  University of Miami Miller School of Medicine, Miami, FL  University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia  Pirogov Russian National Research Medical University, Moscow, Russian Federation  Infectious Diseases Division, Research Institute of the McGill University Health Centre, Montreal, QC, Canada  First Saint Petersburg State Medical University, St Petersburg , Russian Federation  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma B.V, Amsterdam, Netherlands  Novartis Healthcare Private Limited, Hyderabad, India  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain  School of Public Health at Oregon Health & Science University, Portland, OR  

Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis

Author:Bar-Or, Amit   Wiendl, Heinz   De Seze, Jerome   Correale, Jorge   Cross, Anne   Derfuss, Tobias   Selmaj, Krzysztof   Winthrop, Kevin   Giacomini, Paul   Sacca, Francesco   Hu, Xixi   Sullivan, Roseanne   Jehl, Valentine   Boer, Ibolya   Bhatt, Alit   Hauser, Stephen   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.007  

Author Institution:Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA  University of Muenster, Muenster, Germany  University Hospital of Strasbourg, Strasbourg, France  Institute for Neurological Research Dr. Raul Carrea, Buenos Aires, Argentina  Washington University School of Medicine, Clayton, MO  Neurology Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine and Biomedicine, University Hospital and University of Basel, Basel, Switzerland  Center for Neurology, Lodz, Lodz, Poland  Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR  Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada  NSRO Department, University “Federico II” of Naples, Naples, Italy  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma AG, Basel, Switzerland  Novartis Healthcare Pvt. Ltd., Hyderabad, India  UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA